バイオコン・バイオロジクス、ヴィアトリス社バイオシミラー事業の統合を完了し世界最大手へ
Biocon's scale in biosimilars positions India as the global hub for affordable biologics, potentially transforming access to cancer and autoimmune treatments across developing Asia.
Biocon Biologics completed integrating Viatris's biosimilars business, creating the world's largest pure-play biosimilars company with 20+ molecules and commercial presence in 120+ countries.
Biocon Biologics 完成了 Viatris 生物仿制药业务的整合，成为全球最大的纯生物仿制药公司。
Biocon's scale in biosimilars positions India as the global hub for affordable biologics, potentially transforming access to cancer and autoimmune treatments across developing Asia.
Where this signal fits in the broader landscape.
No recent signals tracked yet.
https://www.bioconbiologics.com/our-stories/biocon-biologics-successfully-completes-integration-of-acquired-biosimilars-business-in-120-countries/
Read Full SourceGet curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
Sign in to save notes on signals.
ログイン